首页> 外国专利> Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)

Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)

机译:用选择性雄激素受体调节剂(SARMS)治疗HER2阳性乳腺癌的方法

摘要

This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed SERM (tamoxifen, toremifene), aromatase inhibitor, palbociclib (Ibrance), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, exemestane (Aromasin), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; and/or HER2-positive; comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.
机译:本发明涉及对象,例如女性对象中乳腺癌的治疗。包括以下方法:治疗转移性乳腺癌;难治性乳腺癌AR阳性乳腺癌; AR阳性难治性乳腺癌; AR阳性转移性乳腺癌; AR阳性和ER阳性乳腺癌;三阴性乳腺癌晚期乳腺癌; SERM(他莫昔芬,托瑞米芬),芳香酶抑制剂,palbociclib(Ibrance),曲妥珠单抗(Herceptin,ado-trastuzumab Emtansine),帕妥珠单抗(Perjeta),拉帕替尼,依西美斯汀(Aromasin),贝伐单抗和阿伐单抗(Avastin)氟司韦特治疗;在患有乳腺癌的受试者中的转移;和/或HER2阳性;包括向受试者施用治疗有效量的选择性雄激素受体调节剂(SARM)化合物。

著录项

  • 公开/公告号US10314807B2

    专利类型

  • 公开/公告日2019-06-11

    原文格式PDF

  • 申请/专利权人 GTX INC.;

    申请/专利号US201615371104

  • 申请日2016-12-06

  • 分类号A61K31/167;A61K31/277;A61K31/4704;A61K31/404;A61K9;A61K9/02;A61K9/06;A61K9/08;A61K9/10;A61K9/107;A61K9/16;A61K9/20;A61K9/48;

  • 国家 US

  • 入库时间 2022-08-21 12:17:01

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号